Over the past 6 years, CHI's Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research. The comprehensive 5-day, 12-track program covers immunomodulatory antibody engineering and emerging immuno-oncology targets, combination immunotherapy, preclinical and translational IO, predictive biomarkers and companion diagnostics, adoptive T cell therapy, oncolytic viruses and personalized cancer vaccines.
The Immuno-Oncology Summit brings together a unique and international mix of large and medium pharmaceutical and biotech companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Summit a perfect meeting place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies. Now in its 6th year, the IO Summit consistently delivers a cutting-edge agenda, 600+ senior delegates, and a sold-out exhibit hall.
Please join us in Boston for comprehensive scientific coverage and unparalleled networking opportunities at CHI’s Immuno-Oncology Summit 2018!